Carmat Fails to Meet Heart-Device Goals as Stock Holds Up
This article is for subscribers only.
Carmat SAS surged as much as 8.3 percent after the French medical-device maker said it’s close to the first test of its experimental artificial heart on a human.
The stock jumped as much as 9.50 euros to 124.50 euros, the steepest intraday gain since Feb. 1. The shares traded 7.3 percent higher at 123.43 euros as of 10:28 a.m., giving the Velizy-Villacoublay-based company a market value of 510 million euros ($663 million). The shares have soared more than sixfold since the company’s 2010 stock sale.